6-KThe Wire
GSK plc files 6-K
Filed Jun 12, 2026 · 21d ago · Accession 0001654954-26-005913
Plain English
GSK plc announced that its drug momelotinib has received Orphan Drug Designations from the US FDA and European Medicines Agency for the treatment of VEXAS syndrome. A Phase II/III trial for momelotinib in VEXAS syndrome is underway.
Filing details
- Company
- GSK plc
- Ticker
- GSK
- CIK
- 1131399
- Form type
- 6-K
- Filing date
- Jun 12, 2026
- Report date
- Jun 12, 2026
- Document
- a0204i.htm
- Size
- 50 KB